The global scramble to vaccinate the human race against COVID-19 is bigger than Canadian politics. But every Canadian politician no doubt understands the political and human importance of this country seeming to do well in this multinational competition.
The result this week is anxiety and a rush to assign blame that has failed to produce easy answers to the central question of what, if anything, Canadian officials could be doing to procure more of what’s arguably the most precious commodity on Earth.
But this consternation among Canadian politicians might be obscuring a bigger question for the world: Is this really the best way to go about vaccinating 7.6 billion people against a common threat?
The latest spasm of concern about Canada’s vaccine supply can be traced to a production facility in Puurs, Belgium, where Pfizer has been manufacturing one of the two approved vaccines for use in Canada. Pfizer has decided to retool that facility so that it can increase production. In the short-term, that means fewer doses will be available.
In response to Pfizer’s change of plans, Ontario Premier Doug Ford quickly declared that, if he were prime minister, he’d be on the phone to Pfizer’s top executive demanding the previously scheduled shipments. “I’d be up that guy’s ying-yang so far with a firecracker he wouldn’t know what hit him,” Ford said.
WATCH | Ontario premier says Trudeau’s ‘No. 1 job’ is to get vaccines:
Ontario Premier Doug Ford says Prime Minister Justin Trudeau needs to fight to get the Pfizer-BioNTech COVID-19 vaccine to Canada and he suggests the alternative to the Belgian plant may be Pfizer’s Michigan facility. 0:55
It stands to reason that if getting a plentiful supply of the Pfizer vaccine was as easy as getting up Pfizer CEO Albert Bourla’s ying-yang with a firecracker, nearly every leader on the planet would be doing so. But Ford got a chance to test his theory — a day later he spoke with the president of Pfizer Canada. If a firecracker was lit during that conversation, it has so far failed to change Pfizer’s plans.
In Ottawa, the consternation has been only slightly less colourful, culminating in an “emergency debate” in the House of Commons on Tuesday.
The Conservatives argue that an ill-fated partnership between the National Research Council and China’s CanSino Biologics distracted Justin Trudeau’s government from pursuing better options — but Public Services Minister Anita Anand told the Canadian Press in December that Canada was the fourth country in the world to sign a contract with Pfizer and the first to sign with Moderna, the other major supplier of an approved vaccine.
The New Democrats argue that the federal government should have negotiated for the right to domestically produce the currently approved vaccines — but that presumably depends in large part on the willingness of companies like Moderna and Pfizer to do so.
A real effort to ensure Canada had domestic capacity to produce a pandemic vaccine likely would have had to have been implemented years ago.
Little control over vaccine supply
Eventually, Tuesday night’s debate landed on questions of transparency. The government says it has a plan for vaccinating Canadians, but the opposition says that plan isn’t detailed enough.
The opposition insists the government should release the details of the contracts it has signed with manufacturers, but the government says those contracts are necessarily confidential. There are suggestions that Europe’s supply of the Pfizer vaccine might be smaller than the interruption to Canada’s supply, but it’s not clear why that might be the case.
The Liberals surely understand the gravity of the vaccine race, but they have never shown much interest in explaining themselves in detail. They insist that their agreements with seven potential manufacturers have put Canada in a decent position and that their medium-term and long-term targets for vaccinating Canadians over the course of this year will not be affected by the current shortfall.
WATCH | EU threatens to slow vaccine exports, increasing concerns about vaccine nationalism:
The European Union is threatening to slow exports of the Pfizer vaccine after Astra-Zeneca announced a delay in production. With vaccines in short supply, global health leaders are growing increasingly concerned about the rise of vaccine nationalism. 2:00
But Pfizer’s decision to retool the plant in Puurs underlines how little control the Liberal government can claim to have over the situation and how little sympathy they’ll receive if things don’t work out the way they said they would.
It was just over a month ago that the federal government was able to answer a previous panic with earlier-than-expected approvals and shipments of the new vaccine. If the Liberals were only too happy to bask in that good news, this interruption feels like the universe’s way of telling them to not get cocky.
Canada vs. other countries
In the meantime, even the definition of success will be up for debate.
On Monday, for instance, Conservative MP Pierre Paul-Hus complained that Canada was not doing as well as the Seychelles, which had delivered at least a first dose to 20.22 per cent of its population through January 25. By comparison, Canada’s rate of vaccination was 2.23 per cent.
But the tiny island nation has a population of 98,000 people (roughly the equivalent of Red Deer, Alta). In absolute terms, the number of people who had received a dose in the Seychelles was 19,889. Canada, meanwhile, had administered doses to 839,949 people.
WATCH | Ottawa offers assurances about COVID-19 vaccine supply:
Prime Minister Justin Trudeau is trying to reassure Canadians about the COVID-19 vaccine supply after the European Union raised the possibility of imposing export controls on vaccines leaving the EU. Canada’s Pfizer-BioNTech shots are made in Belgium. 1:44
On Tuesday, Deputy Prime Minister Chrystia Freeland countered that Canada was ahead of Germany, France, Japan, Australia and New Zealand. But three of those countries — Japan, Australia and New Zealand — haven’t yet begun their vaccination programs. And in two of those countries — Australia and New Zealand — COVID-19 is almost non-existent.
‘This is pure nonsense’
During the emergency debate on Tuesday night, the NDP’s Don Davies said Canada ranked 16th per capita in doses administered. He meant it as a complaint. But it could just as easily be framed as a compliment — if Canada ends up being the 16th fastest country to vaccinate its population, it will have finished ahead of 174 other countries. Among the 32 OECD countries who have begun vaccinations, Canada ranks 12th in doses administered per capita.
A few countries — the United States, United Kingdom and Israel — seem to be benefiting from their own unique circumstances. The U.S. and U.K., for instance, have access to domestic production of the available vaccines.
In every other country, there might be some version of the Canadian debate playing out; Trudeau said last week that he and German Chancellor Angela Merkel had commiserated about the similar criticism that they were each facing.
WATCH | COVID’s one year anniversary in Canada:
One year after the first confirmed case of COVID-19, are we really all in it together? A PSW speaks about the reality of working the front lines in long-term care homes, and an artist questions life after CERB. PLUS, why first-world countries like Canada are being accused of hoarding vaccines. 45:36
But all of this might underline the questions of whether an every-country-for-itself scramble to acquire vaccines from a limited number of private manufacturers is the sensible way to go about vaccinating the human race.
“‘Could Canada have done more?’ The problem for me is that this is not the right question. What we’ve been seeing, for me, is a bit of a catastrophe,” said Marc-Andre Gagnon, a political science professor at Carleton University who focuses on pharmaceutical policy.
“You end up with a handful of companies that are developing their own vaccines, each by themselves, working in silos. So then you have a product with a patent, so monopoly rights on the product. And then you end up with this vaccine nationalism of all countries basically doing a free market negotiation in terms of who can jump the queue in order to get faster access to the vaccines. In terms of priorities of global public health, this is pure nonsense.”
A better approach, Gagnon suggests, would have focused on collaboration, data sharing and making use of all available manufacturing capacity around the world.
Pfizer’s new deal with Sanofi, a rival producer, might at least be a step in that direction. But any serious rethinking of global vaccination policy might have to wait for the next pandemic.
TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.
The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.
“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.
The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.
But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.
Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.
“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.
“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”
Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.
The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.
In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.
Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.
The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.
The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.
Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.
Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.
It will also re-evaluate its design ranks.
Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.
Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.
This report by The Canadian Press was first published Sept. 13, 2024.
VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.
No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.
About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.
Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.
Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.
A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”
This report by The Canadian Press was first published Sept. 12, 2024.
MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.
The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.
The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.
Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.
On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.
Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.
This report by The Canadian Press was first published Sept. 12, 2024.
